PA 3670
Alternative Names: PA-3670Latest Information Update: 25 Apr 2024
At a glance
- Originator Zhejiang Palo Alto Pharmaceuticals
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 19 Dec 2023 Zhejiang Palo Alto Pharmaceuticals completes a phase I trial for Hepatitis B (In volunteers) in China (PO) (NCT05851261)
- 13 Apr 2023 Phase-I clinical trials in Hepatitis B (In volunteers) in China (PO) (NCT05851261)